Research programme: infectious disease vaccines - Immunovaccine

Drug Profile

Research programme: infectious disease vaccines - Immunovaccine

Alternative Names: Bacterial vaccines - Immunovaccine; DepoVax™; DPX-Ebola; Malaria vaccine - Immunovaccine

Latest Information Update: 28 Sep 2016

Price : $50

At a glance

  • Originator ImmunoVaccine Technologies
  • Developer Defence Research and Development Canada; Immunovaccine; National Institute of Allergy and Infectious Diseases
  • Class Bacterial vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Bacterial infections; Malaria; Viral haemorrhagic fevers
  • Discontinued Anthrax; Ebola virus infections; Hepatitis B; Influenza virus infections

Most Recent Events

  • 23 Sep 2016 DepoVax malaria vaccine is still in preclinical development for Malaria
  • 16 Sep 2016 Discontinued - Preclinical for Anthrax in Canada (Parenteral)
  • 16 Apr 2015 Discontinued - Preclinical for Ebola virus infections in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top